New drug cocktail takes on hard-to-treat lymphomas
NCT ID NCT03240211
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests whether combining the immunotherapy pembrolizumab (Keytruda) with chemotherapy drugs pralatrexate and decitabine is safe and can shrink tumors in people with relapsed peripheral or cutaneous T-cell lymphoma. About 37 adults whose cancer has returned or not responded to prior treatments will receive different drug combinations. The main goals are to find the best dose and check for early signs of effectiveness.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Pembrolizumab (Keytruda), pralatrexate (Folotyn), and decitabine (Dacogen)
What this could lead to
If successful, this could point toward a new combination treatment for people with relapsed T-cell lymphoma that has stopped responding to standard therapy.
What could go wrong
This is a very early phase 1 trial with only 37 participants, so the main goal is finding a safe dose, not proving it works. Side effects from the drug combinations could be serious, and the approach may not shrink tumors or extend survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CTCL are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Allegheny Health Network
Pittsburgh, Pennsylvania, 15212-4722, United States
-
University of Virginia
Charlottesville, Virginia, 22911, United States